FDA Letter API

University Fertility Laboratory, Inc.

Letter data

Company
University Fertility Laboratory, Inc.
Recipient
Dr. Omid A. Khorram | Medical Director | University Fertility Laboratory, Inc. | 23550 Hawthorne Blvd., Suite 210 | Torrance | , | CA | 90505 | United States | okhorram@yahoo.com
Issue date
2023-08-03
Posted date
Not available
FDA office
Division of Biological Products Operations II
Subject
Not available
Product
Biologics
CMS ID
577584
Reference number
Not available
FEI
Not available
Inspection dates
Not available

Normalized citations

21 CFR: None found

21 U.S.C.: None found

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER University Fertility Laboratory, Inc. MARCS-CMS 577584 — August 03, 2023 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Email Product: Biologics Recipient: Recipient Name Dr. Omid A. Khorram Recipient Title Medical Director University Fertility Laboratory, Inc. 23550 Hawthorne Blvd., Suite 210 Torrance , CA 90505 United States okhorram@yahoo.com Issuing Office: Division of Biological Products Operations II United States Dear Dr. Khorram: The Food and Drug Administration has completed evaluation of your corrective actions in response to our Warning Letter # OBPO 19-006 issued May 30, 2019. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ Amy Graf Compliance Officer Content current as of: 08/10/2023 Regulated Product(s) Biologics